Plain-English translation of NCT06254911 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a drug called , which helps your immune system fight cancer cells. Patients with early-stage throat cancer caused by HPV will receive this medication intravenously (through an IV) before surgery. The trial will watch how safe the treatment is and how well it works to shrink the cancer before your surgeon removes it.
Most people with throat cancer caused by HPV do well with standard treatments, but doctors want to see if boosting the immune system before surgery might help some patients avoid more intensive treatment later or improve their long-term outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive two doses of the medication through an IV before your scheduled surgery. During the study, you'll have CT scans and MRI imaging to monitor your cancer, and your doctors may take a small tissue sample from the tumor. After the medication doses and scans are complete, you will have your standard surgical treatment, and the research team will track how you recover and whether your cancer comes back over the next 2 years.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States